Asthma Drug Market 2023 Forecasts: US, 5EU & Japan Industry Analysis

News provided by

Sep 19, 2014, 08:30 ET

DALLAS, September 19, 2014 /PRNewswire/ --

RnRMarketResearch.com adds asthma drugs market research reports titled "Asthma - Japan Drug Forecast and Market Analysis to 2023", "Asthma - US Drug Forecast and Market Analysis to 2023" and "Asthma - 5EU Drug Forecast and Market Analysis to 2023" to its online library.

According to Asthma - 5EU Drug Forecast and Market Analysis to 2023 research report covering the UK, France, Italy, Spain, Germany, the 2013 base-year market sales of asthma products in France were $918m.The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. Advair's active patent on the Diskus delivery platform in Italy has already expired, but still generates high sales numbers due to the difficulties involved in replicating the delivery technology. GlobalData believes that Advair will slowly lose its dominant position in the Spanish market. This research expects Breo Ellipta to dominate the branded segment of the UK ICS/LABA market, as it is the first complete regimen to be dosed once daily for asthma treatment.

The Asthma - US Drug Forecast and Market Analysis to 2023 research report says that 2013 base-year market sales for asthma pharmaceuticals in the US were around $10.1 billion. As in the global market, this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of numerous SABA, ICS, and ICS/LABA products over the forecast period, will be offset by eight pipeline product launches, seven of which are targeted biologics.

In the Japan Asthma Drug Forecast and Market Analysis to 2023 report, 2013 base-year market sales of asthma products in Japan are shown at $1.7 billion. A dip in sales caused by the Singulair patent expiry in 2013, as well as the patent expiry of the best-selling ICS/LABA FDCs, GSK's Advair and AstraZeneca's Symbicort, will be offset by eight pipeline product launches, seven of which are targeted biologics. Despite the fact that the target patient pool for these biologic therapies will be relatively limited, as they will target only specific subpopulations of severe asthmatics, they will fulfill some of the major unmet needs for the treatment of severe asthmatics who do not respond to conventional treatment with the ICS and ICS/LABA therapies.

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Scope of these 2014-2023 asthma drugs market research reports include:

Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the US, Japan and 5EU (the UK, France, Italy, Spain, Germany) including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the US, Japan and 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting the US, Japan and 5EU (the UK, France, Italy, Spain, Germany) Asthma market.

Reasons To Buy one or more of these US, Japan and 5EU (the UK, France, Italy, Spain, Germany) asthma drug research reports include:

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Asthma.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in the region of your interest.

Explore more reports on pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:

RnR Market Research is an online database of syndicated market research reports covering over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

Connect With Us on:

Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Twitter: https://twitter.com/#!/RnRMR

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

RSS Feed: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research